Trinity Biotech (TRIB) EBITDA Margin (2009 - 2024)

Trinity Biotech (TRIB) has reported EBITDA Margin for 16 consecutive years, with 72.61% the latest figure, recorded in Q4 2024.

• Quarterly EBITDA Margin fell 4446.0% year-over-year to 72.61% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 34.38% (up 1321.0% YoY) and the FY2025 annual result came in at 36.06%, down 168.0% from the prior year.
• EBITDA Margin fell to 72.61% in Q4 2024 per TRIB's latest filing, from 16.88% in the prior quarter.
• Over the last five years, EBITDA Margin for TRIB reached as high as 28.38% in Q3 2020 and fell as low as 106.86% in Q2 2023.
• A 5-year average of 17.79% and a median of 14.44% in 2022 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2023 — EBITDA Margin sank 9486 bps — and 2024, when it soared 8129 bps.
• Year by year, EBITDA Margin stood at 27.67% in 2020, then plunged by 90 bps to 2.88% in 2021, then tumbled by 1899 bps to 51.87% in 2022, then soared by 46 bps to 28.14% in 2023, then slumped by 158 bps to 72.61% in 2024.
• According to Business Quant data, EBITDA Margin over the past three periods registered 72.61%, 16.88%, and 25.58% for Q4 2024, Q3 2024, and Q2 2024 respectively.